Healthy men needed to track how experimental schizophrenia drug leaves the body
NCT ID NCT07455084
First seen Mar 16, 2026 · Last updated May 13, 2026 · Updated 10 times
Summary
This early-stage trial will give 8 healthy men a single radioactive-labeled dose of an experimental schizophrenia drug to see how it is absorbed, broken down, and eliminated. Participants must be in good health and have regular bowel movements. The study does not aim to treat any condition, only to gather information on the drug's journey through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Celerion, Inc.
Lincoln, Nebraska, 68502, United States
Conditions
Explore the condition pages connected to this study.